. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Am J Kidney Dis. 2019 Jul 11;75(1):21–29. doi: 10.1053/j.ajkd.2019.05.010

Table 3.

Unadjusted and adjusted event rates per 100-person years (95% CI) stratified by study and randomization arm

			Enalapril			Placebo
Study	Outcome	Model	N	Events	Event rate	N	Events	Event rate
Treatment Trial	Creatinine Increase by ≥0.3 mg/dl	Unadjusted	1207	349	18.3 (16.5, 20.3)	1216	258	13.2 (11.7, 14.9)
	Creatinine Increase by ≥0.3 mg/dl	Adjusted			17.7 (15.9, 19.8)			12.8 (11.3, 14.5)
	Decline in eGFR by >30%	Unadjusted	1207	298	14.9 (13.3, 16.7)	1216	208	10.2 (8.9, 11.7)
	Decline in eGFR by >30%	Adjusted			13.6 (12.1, 15.3)			9.4 (8.2, 10.8)
	Decline in eGFR by >30%	Unadjusted	1207	133	6.0 (5.0, 7.1)	1216	96	4.5 (3.7, 5.4)
	Decline in eGFR by >30%	Adjusted			5.4 (4.5, 6.5)			4.1 (3.4, 5.1)
	Incident eGFR<30 ml/min/1.73 m²	Unadjusted	1195	61	2.6 (2.1, 3.4)	1207	46	2.1 (1.6, 2.8)
	Incident eGFR<30 ml/min/1.73 m²	Adjusted			0.9 (0.6, 1.3)			0.6 (0.4, 0.9)
Prevention Trial	Creatinine Increase by ≥0.3 mg/dl	Unadjusted	2047	334	8.9 (8.0, 9.9)	2047	273	7.3 (6.5, 8.2)
	Creatinine Increase by ≥0.3 mg/dl	Adjusted			8.3 (7.4, 9.3)			6.8 (6.0, 7.7)
	Decline in eGFR by >30%	Unadjusted	2047	288	7.5 (6.7, 8.4)	2047	236	6.2 (5.5, 7.1)
	Decline in eGFR by >30%	Adjusted			6.5 (5.7, 7.3)			5.4 (4.7, 6.2)
	Decline in eGFR by >40%	Unadjusted	2047	111	2.7 (2.3, 3.3)	2047	85	2.1 (1.7, 2.7)
	Decline in eGFR by >40%	Adjusted			2.2 (1.8, 2.7)			1.7 (1.4, 2.2)
	Incident eGFR<30 ml/min/1.73 m²	Unadjusted	2042	31	0.7 (0.5, 1.1)	2040	27	0.7 (0.5, 1.0)
	Incident eGFR<30 ml/min/1.73 m²	Adjusted			0.3 (0.2, 0.5)			0.2 (0.1, 0.4)

Analyses performed using Poisson regression with the logarithm of the follow-up time as an offset parameter

Adjusted for age, sex, race, NYHA functional class, current smoking, ischemic etiology of left ventricular dysfunction, diuretic use and baseline eGFR. eGFR=estimated glomerular filtration rate